Northwest Bioth Cmn (NWBO): Price and Financial Metrics
GET POWR RATINGS... FREE!
NWBO POWR Grades
- NWBO scores best on the Sentiment dimension, with a Sentiment rank ahead of 54.28% of US stocks.
- The strongest trend for NWBO is in Stability, which has been heading up over the past 31 weeks.
- NWBO ranks lowest in Momentum; there it ranks in the 9th percentile.
NWBO Stock Summary
- NWBO's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.03 -- higher than just 0.11% of US-listed equities with positive expected earnings growth.
- NWBO's price/sales ratio is 1,374.92; that's higher than the P/S ratio of 99.23% of US stocks.
- Over the past twelve months, NWBO has reported earnings growth of -8,574.34%, putting it ahead of just 0.19% of US stocks in our set.
- If you're looking for stocks that are quantitatively similar to Northwest Biotherapeutics Inc, a group of peers worth examining would be ARWR, HPK, NFE, GRWG, and MKL.
- NWBO's SEC filings can be seen here. And to visit Northwest Biotherapeutics Inc's official web site, go to www.nwbio.com.
NWBO Stock Price Chart Interactive Chart >
NWBO Price/Volume Stats
| Current price | $1.48 | 52-week high | $2.51 |
| Prev. close | $1.54 | 52-week low | $0.26 |
| Day low | $1.48 | Volume | 1,545,605 |
| Day high | $1.56 | Avg. volume | 2,112,927 |
| 50-day MA | $1.53 | Dividend yield | N/A |
| 200-day MA | $1.38 | Market Cap | 1.26B |
Northwest Bioth Cmn (NWBO) Company Bio
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies. The company was founded in 1996 and is based in Bethesda, Maryland.
Latest NWBO News From Around the Web
Below are the latest news stories about Northwest Biotherapeutics Inc that investors may wish to consider to help them evaluate NWBO as an investment opportunity.
UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that an application for certification of the manufacturing facility in Sawston, UK has been submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA). The Company also provided a process update on the DCVax®-L Phase III Trial. |
Is Northwest Biotheraputics a Buy Ahead of Its Brain Tumor Vaccine Clinical Data Release?In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0. |
Northwest Biotherapeutics Announces Data Lock of Phase III TrialNorthwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the database for the Phase III trial of DCVax®-L for Gliobastoma has been locked. |
Northwest Biotherapeutics Acquires FlaskworksNorthwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has acquired Flaskworks, a company that has developed a breakthrough system to close and automate the manufacturing of cell therapy products such as DCVax®. |
Northwest Biotherapeutics Announces $8 Million FinancingNorthwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a financing on favorable terms for approximately $8 million. The Company anticipates that this financing will help maintain the Company's momentum, and will provide some prudent protection in the midst of the current global economic uncertainties. The financing also further broadens the lock-up of warrants that the Company has been building. |
NWBO Price Returns
| 1-mo | -6.33% |
| 3-mo | -6.92% |
| 6-mo | 8.82% |
| 1-year | 291.53% |
| 3-year | 448.15% |
| 5-year | 138.71% |
| YTD | -2.95% |
| 2020 | 609.63% |
| 2019 | 4.57% |
| 2018 | -12.63% |
| 2017 | -32.43% |
| 2016 | -89.12% |
Continue Researching NWBO
Want to do more research on Northwest Biotherapeutics Inc's stock and its price? Try the links below:Northwest Biotherapeutics Inc (NWBO) Stock Price | Nasdaq
Northwest Biotherapeutics Inc (NWBO) Stock Quote, History and News - Yahoo Finance
Northwest Biotherapeutics Inc (NWBO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...